BioMarker Strategies is a privately held, Maryland-based limited-liability company located at the Johns Hopkins Science + Technology Park. The company, which was founded in 2006, has raised more than $9 million in start-up capital from private investors, including the Abell Foundation. BioMarker Strategies was also awarded a Fast-Track SBIR contract for $2.3 million from the National Cancer Institute in the fall of 2009 to expedite the development of the SnapPath™ ex vivo biomarker platform. The company was awarded an additional Phase I SBIR contract from the NCI in September of 2011 to fund the development of a companion diagnostic test for drugs targeting the ErbB signaling network. The company has also received grants from the Maryland Technology Development Corporation and Johnson & Johnson to support the development of the SnapPath™ platform .

For more information about investment opportunities at the company, please contact
Scott Allocco at sallocco@biomarkerstrategies.com.